ABL-002

N/A

Report date: 2023/02/09 18:30:52

Base Information

Drug NameABL-002

Drug Alias NameABL002

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsHead and Neck Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAbl Bio Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAbl Bio Inc

Active IndicationsN/A

Inactive IndicationsHead and Neck Neoplasms

Other Information

ATC CodeN/A